Ceramide is increased in the lower airway epithelium of people with advanced cystic fibrosis lung disease

American Journal of Respiratory and Critical Care Medicine

Volumn 182, Issue 3, 2010, Pages 369-375

  Brodlie, Malcolm ^a,b   McKean, Michael C ^b   Johnson, Gail E ^b   Gray, Joe ^a   Fisher, Andrew J ^a,b   Corris, Paul A ^a,b   Lordan, James L ^b   Ward, Christopher ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Emphysema; Inflammation; Sphingolipid; Transplantation

Indexed keywords

CERAMIDE; LEUKOCYTE ELASTASE; MYELOPEROXIDASE; PEROXIDASE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTIC FIBROSIS; CYSTIC FIBROSIS LUNG DISEASE; EMPHYSEMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG FIBROSIS; MASS SPECTROMETRY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PULMONARY HYPERTENSION; RESPIRATORY EPITHELIUM; STAINING; HOSPITALIZATION; LUNG; LUNG EMPHYSEMA; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; RESPIRATORY TRACT MUCOSA;

ADOLESCENT; ADULT; CERAMIDES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTIC FIBROSIS; HUMANS; HYPERTENSION, PULMONARY; IMMUNOHISTOCHEMISTRY; LEUKOCYTE ELASTASE; LUNG; MASS SPECTROMETRY; MIDDLE AGED; PEROXIDASE; PSEUDOMONAS AERUGINOSA; PULMONARY EMPHYSEMA; RESPIRATORY MUCOSA; SEVERITY OF ILLNESS INDEX;

EID: 77956641729     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200905-0799OC     Document Type: Article

References (42)

1. Ratjen F. Update in cystic fibrosis 2008. Am J Respir Crit Care Med 2009;179:445-448.
2. Doring G, Elborn JS, Johannesson M, de Jonge H, Griese M, Smyth A, Heijerman H. Clinical trials in cystic fibrosis. J Cyst Fibros 2007;6:85-99.
3. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007;29:522-526.
4. Meachery G, De Soyza A, Nicholson A, Parry G, Hasan A, Tocewicz K, Pillay T, Clark S, Lordan JL, Schueler S, et al. Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax 2008;63:725-731.
5. Uhlig S, Gulbins E. Sphingolipids in the lungs. Am J Respir Crit Care Med 2008;178:1100-1114.
6. Niessen F, Schaffner F, Furlan-Freguia C, Pawlinski R, Bhattacharjee G, Chun J, Derian CK, Andrade-Gordon P, Rosen H, Ruf W. Dendritic cell PAR1 - S1P3 signalling couples coagulation and inflammation. Nature 2008;452:654-658.
7. Oskeritzian CA, Milstien S, Spiegel S. Sphingosine-1-phosphate in allergic responses, asthma and anaphylaxis. Pharmacol Ther 2007;115:390-399.
8. Teichgraber V, Ulrich M, Endlich N, Riethmuller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kurthy G, Schmid KW, et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008;14:382-391.
9. Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C, Hubbard WC, Berdyshev EV, Tuder RM. Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med 2005;11:491-498.
10. Grassme H, Riehle A, Wilker B, Gulbins E. Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms. J Biol Chem 2005;280:26256-26262.
11. Noe J, Petrusca D, Rush N, Deng P, Vandemark M, Berdyshev E, Gu Y, Smith P, Schweitzer K, Pilewsky J, et al. CFTR regulation of intracellular pH and ceramides is required for lung endothelial cell apoptosis. Am J Respir Cell Mol Biol 2009;41:314-323.
12. Davidson DJ, Dorin JR, McLachlan G, Ranaldi V, Lamb D, Doherty C, Govan J, Porteous DJ. Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens. Nat Genet 1995;9:351-357.
13. Downey DG, Bell SC, Elborn JS. Neutrophils in cystic fibrosis. Thorax 2009;64:81-88.
14. Becker KA, Riethmuller J, Luth A, Doring G, Kleuser B, Gulbins E. Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am J Respir Cell Mol Biol 2009;Epub Jul 27.
15. Guilbault C, Wojewodka G, Saeed Z, Hajduch M, Matouk E, De Sanctis JB, Radzioch D. Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. Am J Respir Cell Mol Biol 2008;41:100-106.
16. Guilbault C, De Sanctis JB, Wojewodka G, Saeed Z, Lachance C, Skinner TA, Vilela RM, Kubow S, Lands LC, Hajduch M, et al. Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am J Respir Cell Mol Biol 2008;38:47-56.
17. Yu H, Zeidan YH, Wu BX, Jenkins RW, Flotte TR, Hannun YA, Virella-Lowell I. Defective acid sphingomyelinase pathway with Pseudomonas aeruginosa infection in cystic fibrosis. Am J Respir Cell Mol Biol 2009;41:367-375.
18. Hamutcu R, Rowland JM, Horn MV, Kaminsky C, MacLaughlin EF, Starnes VA, Woo MS. Clinical findings and lung pathology in children with cystic fibrosis. Am J Respir Crit Care Med 2002;165:1172-1175.
19. Hays SR, Fahy JV. Characterizing mucous cell remodeling in cystic fibrosis: relationship to neutrophils. Am J Respir Crit Care Med 2006;174:1018-1024.
20. Brodlie M, McKean MC, Johnson GE, Fisher AJ, Corris PA, Lordan JL, Ward C. Ceramide is increased and associated with neutrophilic inflammation in the lower airway epithelium of people with cystic fibrosis. Thorax 2009;64:A70-A71.
21. Brodlie M, McKean MC, Johnson G, Fisher AJ, Corris PA, Lordan J, Ward C. Ceramide is a potential biomarker of epithelial injury which is raised in the airway of people with cystic fibrosis. Paper presented at the New Frontiers In Basic Science of Cystic Fibrosis European Cystic Fibrosis Society meeting. 15-19 April 2009, Tavira, Portugal.
22. Brodlie M, McKean MC, Johnson G, Fisher AJ, Corris PA, Lordan J, Ward C. Ceramide is increased and associated with neutrophilic inflammation in the lower airway epithelium of people with cystic fibrosis. Paper presented at 8th ERS Lung Science Conference. 26-28 March 2010, Estoril, Portugal.
23. Ward C, Forrest IA, Murphy DM, Johnson GE, Robertson H, Cawston TE, Fisher AJ, Dark JH, Lordan JL, Kirby JA, et al. Phenotype of airway epithelial cells suggests epithelial to mesenchymal cell transition in clinically stable lung transplant recipients. Thorax 2005;60:865-871.
24. Cowart LA, Szulc Z, Bielawska A, Hannun YA. Structural determinants of sphingolipid recognition by commercially available anti-ceramide antibodies. J Lipid Res 2002;43:2042-2048.
25. Vielhaber G, Brade L, Lindner B, Pfeiffer S, Wepf R, Hintze U, Wittern KP, Brade H. Mouse anti-ceramide antiserum: a specific tool for the detection of endogenous ceramide. Glycobiology 2001;11:451-457.
26. Folch J, Lees M, Sloane-Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226:497-509.
27. Mann HB, Whitney DR. On a test whether one of two random variables is statistically larger than the other. Ann Math Stat 1947;18:50-60.
28. Forrest IA, Murphy DM, Ward C, Jones D, Johnson GE, Archer L, Gould FK, Cawston TE, Lordan JL, Corris PA. Primary airway epithelial cell culture from lung transplant recipients. Eur Respir J 2005;26:1080-1085.
29. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310.
30. Petrache I, Medler TR, Richter AT, Kamocki K, Chukwueke U, Zhen L, Gu Y, Adamowicz J, Schweitzer KS, Hubbard WC, et al. Superoxide dismutase protects against apoptosis and alveolar enlargement induced by ceramide. Am J Physiol 2008;295:L44-L53.
31. Grassme H, Jendrossek V, Riehle A, von Kurthy G, Berger J, Schwarz H, Weller M, Kolesnick R, Gulbins E. Host defense against Pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med 2003;9:322-330.
32. Nieuwenhuis EE, Matsumoto T, Exley M, Schleipman RA, Glickman J, Bailey DT, Corazza N, Colgan SP, Onderdonk AB, Blumberg RS. CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat Med 2002;8:588-593.
33. Haggie PM, Verkman AS. Defective organellar acidification as a cause of cystic fibrosis lung disease: re-examination of a recurring hypothesis. Am J Physiol 2009;296:L859-L867.
34. Haggie PM, Verkman AS. Unimpaired lysosomal acidification in respiratory epithelial cells in cystic fibrosis. J Biol Chem 2009;284:7681-7686.
35. Di A, Brown ME, Deriy LV, Li C, Szeto FL, Chen Y, Huang P, Tong J, Naren AP, Bindokas V, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006;8:933-944.
36. Poschet JF, Skidmore J, Boucher JC, Firoved AM, Van Dyke RW, Deretic V. Hyperacidification of cellubrevin endocytic compartments and defective endosomal recycling in cystic fibrosis respiratory epithelial cells. J Biol Chem 2002;277:13959-13965.
37. Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2009;154:183-188.
38. Pier GB. Dropping acid to help cystic fibrosis. Nat Med 2008;14:367-369.
39. Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, Defronzo RA, Kirwan JP. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 2009;58:337-343.
40. Hamai H, Keyserman F, Quittell LM, Worgall TS. Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling. J Lipid Res 2009;50:1101-1108.
41. Brodlie M, McKean MC, Johnson GE, Perry JD, Nicholson A, Verdon B, Gray MA, Dark JH, Pearson JP, Fisher AJ, et al. Primary bronchial epithelial cell culture from explanted cystic fibrosis lungs. Exp Lung Res 2010;36:101-110.
42. Murphy TF, Brauer AL, Eschberger K, Lobbins P, Grove L, Cai X, Sethi S. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;177:853-860.